SIBN at a glance
SI-BONE, Inc. (SIBN, SEC CIK 1459839) filed its latest 10-K annual report on February 24, 2026, a 10-Q quarterly report on August 4, 2026, an 8-K current report on September 11, 2026 and Form 4 insider filings as recently as October 6, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), SI-BONE, Inc. (SIBN) reported revenue of $200.9 million (up 20.2% from FY2024) and a net loss of $18.9 million. Diluted EPS was -$0.44.
- As of June 30, 2026, 26 institutional investment managers tracked by SignalX reported holding SI-BONE, Inc. (SIBN) shares worth $178.1 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Maheshwari Anshul on October 5, 2026 of 1,731 shares at $19.50 per share.
- In the last 90 days, SIBN insiders reported 0 open-market purchases ($0) and 25 open-market sales ($3.9M) on Form 4, a net sale of $3.9M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $200.9M
- +20.2% vs prior year
- Insiders · 90 days
- 0 buys · 25 sells
- Net −$3.9M
- 13F holders
- 26 funds
- $178.1M · −2 vs prior quarter
- Latest 8-K
- Sep 11, 2026
- Item 1.01 · Item 8.01
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- Quarterly revenue $56.0M, up 15.2% YoY from $48.6M, driven by 14.9% higher procedure volumes
- Gross margin 79.5% vs 79.8% YoY, reflecting product mix changes
- U.S. revenue $53.2M, up 14.7%; international revenue $2.8M, up 25.9%
- Cash and marketable securities $145.9M vs $147.8M at December 31, 2025
- Six-month operating cash use $1.6M vs $4.7M; management expects funding for 12 months but cites downturn and capital-market risks
Risk Factors
- No risk-factors section provided; supplied text begins with Item 2 and contains no 10-Q risk disclosures
- CEO Rule 10b5-1 plan adopted May 21, 2026, covering up to 492,961 shares through August 31, 2027
- Third Amendment to lease dated June 5, 2026, with BIXBY SPE FINANCE 11, LLC
- No regulatory, legal, operational, competitive, market, liquidity, debt, currency, or concentration risks stated in the provided text
AI summary of the SIBN 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 1.01: Entry into a Material Definitive Agreement
- Headquarters lease extended one month through October 31, 2026
- $43,696 October base rent for 21,848 square feet in Santa Clara
Item 8.01: Other Events
- Voluntary recall of 98 iFuse TORQ implants over packaging sterility-barrier failures and potential infection risk
- Two recalled implants were implanted; no infections or adverse events reported as of filing date
Item 2.02: Results of Operations and Financial Condition
- No substantive Item 2.02 earnings information in the provided text
Item EX-99.1: Item EX-99.1
- Q2 revenue $56.0M, up 15.2%, with U.S. procedure volume growth of 14.9%
- Adjusted EBITDA $2.8M versus $1.0M, while net loss narrowed to $4.1M from $6.2M
Item 1.01: Entry into a Material Definitive Agreement
- Lease extended for 21,848-square-foot Santa Clara headquarters through August 31, 2026
- Base rent of $43,696 per month during the extension
Item 5.07: Submission of Matters to a Vote of Security Holders
- 38,905,031 shares represented, approximately 88% of outstanding voting shares
- Jeffrey W. Dunn and John G. Freund re-elected as directors through 2029
AI summaries of SIBN 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for SIBN
Don't miss the next SIBN filing
- Alerts as it files. A push when SIBN files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut SIBN, by share count.
- Ask anything. An AI agent that reads every SIBN filing and answers with sources.
SIBN alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Maheshwari Anshul | Sell | Oct 5, 2026 | 1,731 | $19.50 |
| Maheshwari Anshul | Sell | Oct 2, 2026 | 1,758 | $18.19 |
| PISETSKY MICHAEL A. | Sell | Oct 2, 2026 | 1,300 | $18.20 |
| Maheshwari Anshul | Sell | Oct 2, 2026 | 1,560 | $18.17 |
| PISETSKY MICHAEL A. | Sell | Oct 2, 2026 | 34 | $18.14 |
| PISETSKY MICHAEL A. | Sell | Oct 2, 2026 | 1,799 | $18.14 |
| DUNN JEFFREY W | M | Oct 1, 2026 | 20,000 | - |
| DUNN JEFFREY W | M | Oct 1, 2026 | 20,000 | $4.68 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $167.2M | $200.9M |
| Gross Profit | - | $132.1M | $159.9M |
| Operating Income | - | -$35.2M | -$22.3M |
| Net Income | - | -$30.9M | -$18.9M |
| Gross Margin | - | 79.0% | 79.6% |
| Op. Margin | - | -21.1% | -11.1% |
| Net Margin | - | -18.5% | -9.4% |
| Balance Sheet | |||
| Total Assets | $230.4M | $230.4M | $238.6M |
| Equity | - | $167.0M | $177.5M |
| ROE | - | -18.5% | -10.6% |
| Per Share | |||
| EPS | - | $-0.75 | $-0.44 |
| Cash Flow | |||
| Operating CF | - | -$12.4M | -$675K |
| CapEx | $7.8M | $10.5M | $8.4M |
Source: XBRL data in SI-BONE, Inc. (SIBN)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate SIBN share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 26 | $178.1M |
| Q1 2026 | 28 | $143.5M |
| Q4 2025 | 25 | $218.5M |
| Q3 2025 | 25 | $164.5M |
| Q2 2025 | 25 | $207.4M |
| Q1 2025 | 21 | $92.4M |
| Q4 2024 | 16 | $70.3M |
| Q3 2024 | 13 | $32.2M |
- BlackRock+247.7K (+7%)
- AQR Capital Management+196.1K (+340%)
- Vanguard Portfolio Management LLC+134.8K (+33%)
- Dimensional Fund Advisors+89.4K (+14%)
- State Street Corp+84.5K (+7%)
- Morgan Stanley−581.6K (-82%)
- Renaissance Technologies LLC−428.5K (-91%)
- Goldman Sachs Group−180.5K (-29%)
- Raymond James Financial−31.9K (-63%)
- JPMorgan Chase & Co−29.4K (-23%)
- Allstate+27.5K
- Citadel Advisors LLC−188.2K
- Two Sigma Investments−58.1K
- U.S. Bancorp−18
Source: 13F-HR filings on SEC EDGAR (aggregated from 179 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
SIBN filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Oct 6, 2026 | - | - | - |
| 4 | Oct 6, 2026 | - | - | - |
| 4 | Oct 5, 2026 | - | - | - |
| 8-K | Sep 11, 2026 | - | Analysis | - |
| 4 | Sep 3, 2026 | - | - | - |
| 4 | Aug 26, 2026 | - | - | - |
| 4 | Aug 26, 2026 | - | - | - |
| 4 | Aug 21, 2026 | - | - | - |
| 4 | Aug 21, 2026 | - | - | - |
| 4 | Aug 18, 2026 | - | - | - |
| 4 | Aug 18, 2026 | - | - | - |
| 4 | Aug 18, 2026 | - | - | - |
| SC 13G | Aug 14, 2026 | - | - | |
| 4 | Aug 5, 2026 | - | - | - |
| 10-Q | Aug 4, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 3, 2026 | - | Analysis | - |
| 4 | Jul 6, 2026 | - | - | - |
| 4 | Jul 6, 2026 | - | - | - |
| 4 | Jun 9, 2026 | - | - | |
| 4 | Jun 8, 2026 | - | - | |
| 8-K | Jun 8, 2026 | - | Analysis | |
| 4 | Jun 8, 2026 | - | - | |
| 4 | Jun 8, 2026 | - | - | |
| 4 | Jun 8, 2026 | - | - | |
| 4 | Jun 8, 2026 | - | - |
Related Health Care companies
- ARAY · ACCURAY INCSurgical & Medical Instruments & Apparatus
- ATEC · Alphatec Holdings, Inc.Surgical & Medical Instruments & Apparatus
- ANGO · ANGIODYNAMICS INCSurgical & Medical Instruments & Apparatus
- ANIK · Anika Therapeutics, Inc.Surgical & Medical Instruments & Apparatus
- AORT · ARTIVION, INC.Surgical & Medical Instruments & Apparatus
- ATRC · AtriCure, Inc.Surgical & Medical Instruments & Apparatus
- RCEL · AVITA Medical, Inc.Surgical & Medical Instruments & Apparatus
- BAX · Baxter InternationalSurgical & Medical Instruments & Apparatus
SIBN SEC filings: frequently asked questions
Are SIBN insiders buying or selling?
In the last 90 days, SI-BONE, Inc. (SIBN) officers, directors and 10% owners reported no open-market purchases and 25 open-market sales worth $3.9 million by 4 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold SIBN stock?
As of June 30, 2026, the largest SI-BONE, Inc. (SIBN) holders among the 13F filers tracked by SignalX were BlackRock ($60.0 million), Vanguard Capital Management LLC ($30.0 million), State Street Corp ($19.8 million), Dimensional Fund Advisors ($11.6 million), Vanguard Portfolio Management LLC ($8.9 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was SIBN's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), SI-BONE, Inc. (SIBN) reported revenue of $200.9 million (up 20.2% from FY2024) and a net loss of $18.9 million. Diluted EPS was -$0.44. The figures come from the XBRL data in the 10-K.
What did SIBN report in its latest 8-K?
SI-BONE, Inc. (SIBN) filed an 8-K on September 11, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement) and Item 8.01 (Other Events). Headquarters lease extended one month through October 31, 2026.
What are the latest SIBN SEC filings?
SI-BONE, Inc. (SIBN) filed its latest 10-K annual report on February 24, 2026, a 10-Q quarterly report on August 4, 2026, an 8-K current report on September 11, 2026 and a Form 4 insider filing on October 6, 2026.
What is SIBN's SEC CIK number?
SI-BONE, Inc. (SIBN)'s SEC Central Index Key (CIK) is 1459839. EDGAR lists every SIBN filing under that number.
Ask anything about SIBN
The research agent reads SIBN's filings, financials, insider trades and 13F holders, then answers with sources.